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Myocardial MIBG scintigraphy is established in the diagnosis and diﬀerential diagnosis of Parkinson’s disease (PD). Numerous
studies address the pathophysiological impact of myocardial MIBG scintigraphy: the myocardial MIBG uptake correlates with
the clinical phenotype of PD; the background of this phenomenon is unclear. Furthermore MIBG scintigraphy enables to study
the extracranial Lewy body type-degeneration. In combination with cerebral dopamine transporter imaging, MIBG scintigraphy
allows to correlate cerebral and extracranial Lewy body type-degeneration in PD.
1.Introduction
Metaiodobenzylguanidine (MIBG) is a norepinephrine
(noradrenaline) analogue which competes with nore-
pinephrine for the same cellular transporter mechanisms
of postganglionic adrenergic neurons. Like norepinephrine,
MIBG is actively transported into noradrenaline granules
of sympathetic nerve terminals by the noradrenaline trans-
porter (uptake 1 mechanism; [1]). MIBG has no pharma-
cological activity. Due to its aﬃnity to sympathetic nerve
endings MIBG accumulates predominantly in organs with a
high sympathetic activity such as the adrenal gland, the liver,
the spleen, the heart, and the salivary glands [2]. For diag-
nostic purposes MIBG is marked by a radioactive isotope,
for example, 123-iodine (123I). The accumulation of MIBG is
visualized and measured by planar whole-body scintigraphy.
In clinical practice, the MIBG scintigraphy is mainly used
to detect (and sometimes to treat) neuroendocrine tumours,
primarily pheochromocytomas and neuroblastomas [3–8].
2. MIBG Scintigraphy inthe Diagnosisof
Parkinson’sDisease
The myocardial MIBG scintigraphy measures the postgan-
glionic sympathetic cardiac innervation (Figure 1). In the
nineties of the last century it was observed that patients
with Parkinson’s disease (PD) disclose a signiﬁcantly lower
myocardial MIBG uptake than healthy controls (Figures
1–3,[ 9, 10]). This observation of a reduced myocardial
MIBG uptake in PD was reproduced in numerous studies
(Table 1). The reduced myocardial MIBG uptake reﬂects
the sympathetic myocardial degeneration in PD and results
from a Lewy body type-degeneration of the cardiac plexus
[11–13]. MIBG scintigraphy is measured 15 minutes (early
registration) and four hours (late registration) after intra-
venous MIBG application. The early registration mainly
correlates with the inﬂux of MIBG into extraneural spaces
in the myocardial tissue rather than into neural components.
The late registration displays the neuronal uptake of MIBG
more explicitly and correlates with the functional status
of sympathetic nerve terminals [14–16]. Therefore the late
registration is more relevant in clinical practice [17]. All data
in the following refer to the late registration. The myocardial
MIBG uptake is quantiﬁed by the relation between MIBG
uptake in the heart (more exactly: myocardium) versus
MIBGuptakeinthemediastinum.Theheart-to-mediastinum
ratio (H/M ratio) is calculated as the quotient [counts per
pixel in the myocardium]/[counts per pixel in the upper
mediastium] [17, 18]. PD patients show a signiﬁcantly lower
H/M ratio than healthy controls [9–13]. For this reason,
MIBG scintigraphy may be helpful in the diagnosis of PD.
Most studies did not ﬁnd any signiﬁcant correlation between
myocardial MIBG uptake versus gender [19], age, disease
duration or Hoehn and Yahr stage in PD [18, 20–24].2 Parkinson’s Disease
Figure 1: MIBG scintigraphy in a healthy volunteer. Anterior-
posteriorviewina64-year-oldhealthyvolunteer.Themeasurement
was performed four hours after intravenous MIBG application.
There is an intensive myocardial MIBG uptake (black arrow).
Figure 2: MIBG scintigraphy in tremor dominant PD. MIBG
scintigraphy in a 62-year-old male patient with tremor dominant
PD, Hoehn and Yahr stage I. The myocardial MIBG uptake (black
arrow) is well visible but pathologically reduced.
3. Factors Interfering with
MyocardialMIBG Scintigraphy
Coronary heart disease represents an exclusion criterion
for myocardial MIBG scintigraphy, since a myocardial
hypoperfusion due to coronary heart disease may inﬂuence
myocardial MIBG scintigraphy. 99mTc-Metoxy-Isopropyl-
Isonitril (MIBI) scintigraphy can detect a local myocardial
hypoperfusion [25]. Therefore MIBI scintigraphy, prior to
MIBG scintigraphy, is meaningful to exclude a myocardial
hypoperfusion. Primary or secondary cardiomyopathies of
each type are further exclusion criteria for MIBG scintig-
raphy [26–30]. In addition, several drugs may inﬂuence
myocardial MIBG uptake and should be paused before the
MIBG study: for instance, tricyclic and tetracyclic antide-
pressantsaswellasreserpineblockmyocardialMIBGuptake.
Figure 3: MIBG scintigraphy in akinetic rigid PD. MIBG scintigra-
phy in a 65-year old male patient with akinetic rigid type of PD,
Hoehn and Yahr stage I. There is hardly any myocardial MIBG
uptake (black arrow).
Calcium antagonists increase or prolong the myocardial
uptake of MIBG [14, 31, 32]. A detailed list of “forbidden”
drugs was published by Solanki et al. [32].
4. SensitivityandSpeciﬁcityof
MIBG Scintigraphy
PD is diagnosed clinically. The UK Brain Bank criteria
[33] represent the most frequently applied clinical criteria
for diagnosis of PD. The UK Brain Bank criteria were
deﬁned by clinical intravitam symptoms of these patients,
in whom PD diagnosis was conﬁrmed neuropathologically.
The speciﬁcity of these criteria amounts to 93% [34]. This
means that—despite a conscientious clinical examination—
7% of clinically diagnosed PD patients have—in reality—no
PD. This fact requires the use of nuclear medicine methods
in diagnostically unclear patients. Most studies found a high
sensitivity of MIBG scintigraphy in the Hoehn and Yahr
s t a g eIo fP D .H o w e v e r ,ap r e v i o u ss t u d y[ 35] claimed a
broad overlap between healthy controls and PD patients at
Hoehn and Yahr stage I indicating a rather low sensitivity
in the initial stage of PD; the published data of this study
do not allow the calculation of sensitivity or speciﬁcity of
MIBG scintigraphy in this study. To sum up one may say
t h a tar e d u c e dm y o c a r d i a lM I B Gu p t a k es u p p o r t ss u p p o r t
the clinical diagnosis of PD even in the initial stage of PD.
In the more advanced Hoehn and Yahr stages II–V, MIBG
scintigraphy reveals a high sensitivity for PD (Table 1). The
followingsections address the speciﬁcity of MIBG scintigra-
phy concerning PD versus other extrapyramidal diseases.
4.1. Lewy Body Dementia. PD and Lewy body dementia
(LBD) share a common pathology with a Lewy body
type-degeneration of the nervous system. The anatomical
distribution of this Lewy body type-degeneration—in PD
primarily in the basal ganglia, in LBD primarily in cortical
areas—decides whether the patient shows clinical symptomsParkinson’s Disease 3
Table 1: Sensitivity and speciﬁcity of MIBG scintigraphy in Parkinson’s disease. N: total number of investigated patients in the cited study;
APS: atypical Parkinsonian syndromes; Mean H & Y: arithmetical mean of Hoehn and Yahr stage of the PD patients. The strongly varying
speciﬁcity may be caused by the variable distribution of the diagnoses of the patients with atypical parkinsonian syndromes. The lower
norm value was calculated as mean −2.5 standard deviations (if not declared otherwise in the original papers). All data belong to the delayed
imaging four hours after intravenous MIBG application.
Study N Patients with PD/Hoehn and Yahr stage Patients with APS Sensitivity Speciﬁcity
Yoshita [36]5 4 n = 25/mean H & Y = 2.1 n = 29 1.00 0.79
Orimo et al. [37]6 8 n = 45/mean H & Y = 3.0 n = 23 0.80 0.87
Taki et al. [24]7 0 n = 41/mean H & Y = 1.9 n = 29 0.90 0.76
Braune [14] 291 n = 246/H & Y ≥ 2 n = 45 0.90 0.94
Spiegel et al. [38] 102 n = 102/mean H & Y = 1,7 — 0.96 —
Sewada et al. [17] 400 n = 267/mean H & Y = 3.2 n = 133 0.84 0.89
of PD or LBD. Both diseases, PD and LBD, are characterized
by a remarkable Lewy body type-degeneration of postgan-
glionic myocardial sympathetic neurons. Therefore MIBG
scintigraphy discloses a pathologically reduced myocardial
MIBG uptake in both PD and LBD patients [13, 39].
Myocardial MIBG uptake is slightly more reduced in LBD
than in PD patients [23, 40]. But due to the broad overlap
betweenLBDandPD,myocardialMIBGscintigraphycannot
diﬀerentiate between both diseases [13, 23, 35, 39, 40].
4.2. Hereditary Parkinsonism. There exist only small data to
MIBG scintigraphy in hereditary Parkinsonism (HP): Quat-
trone et al. [41] reported a normal myocardial MIBG uptake
in all ten healthy subjects, eight of 14 HP patients, but none
of 15 PD patients. Orimo et al. [42]f o u n dan o r m a lM I B G
scintigraphy in two HP patients with a homozygous PARK2
mutation. These studies suggest that MIBG scintigraphy is
normal or less impaired in HP. Patients, who fulﬁl the UK
Brain Bank criteria for PD but disclose a normal MIBG
scintigraphy, might have HP. The family history may be
inconspicuous, since autosomal recessive forms of HP occur.
4.3. Multiple System Atrophy. In multiple system atrophy
(MSA), the autonomic nervous system is mainly aﬀected in
its preganglionic structures, whereas postganglionic involve-
ment of the autonomic nervous system predominates in PD
[43]. Following this pathoanatomical diﬀerences, it might be
expected that myocardial MIBG uptake is reduced in PD and
normal in MSA. Seen from this angle, MIBG scintigraphy
might be suitable to distinguish between PD and MSA.
Indeed,mostMSApatientsshowanormalmyocardialMIBG
uptake [14, 24, 35–37, 44, 45]. The speciﬁcity of MIBG
scintigraphyconcerningPDagainstMSAvariesbetween0.70
and 0.95 ([35]: 0.79, [44]: 0.70, [14]: 0.95, [37]: 0.86, [24]:
0.78, [36]: 0.80).
4.4. Corticobasal Degeneration. Orimo et al. [46]r e p o r t e da
normal myocardial MIBG scintigraphy in all eight patients
with corticobasal degeneration (CBD), which was not sig-
niﬁcantly diﬀerent from that of healthy controls. Taki et al.
[24] found a normal myocardial MIBG uptake in two CBD
patients. These small case series might suggest that MIBG
scintigraphy diﬀerentiates between PD and CBD, but this
diﬀerence has to be conﬁrmed in larger patient groups.
4.5. Progressive Supranuclear Palsy. Small case series dis-
closed contradictory ﬁndings: Nagayama et al. [35]o b s e r v e d
a reduced myocardial MIBG uptake in six of seven patients
with progressive supranuclear palsy (PSP), whereas Taki
et al. [24] and Yoshita [36] described a reduced myocardial
MIBG uptake only in one of six and three of 14 patients,
respectively. Similar to CBD, studies with larger case num-
bers are necessary to clarify the diagnostic value of MIBG
scintigraphy in PSP.
4.6. Essential Tremor. Patients with essential tremor (ET)
reveal a normal myocardial MIBG uptake, as reported by Lee
et al. [47] in 22 ET patients and by Orimo et al. [37]i nﬁ v e
ETpatients.MIBGscintigraphyclearlydistinguishespatients
withET frompatients withPD, even frompatients with early
PD or tremor-dominant PD which is sometimes very similar
to ET.
5. Correlationof MIBG Scintigraphy with
ClinicalParameters
5.1. Autonomous Functions. Since myocardial MIBG scintig-
raphy measures the sympathetic myocardial function, it
is of interest whether myocardial MIBG uptake correlates
with other autonomous functions. The autonomous nervous
system can be investigated by means of several clinical tests
such as orthostatic reaction, deep breathing, or Valsalva
manoeuvre. During these clinical tests, the blood pressure
(regulated mainly by the sympathetic nervous system), the
heart rate, and variability of heart rate (regulated mainly
by the parasympathetic nervous system) are measured [48].
There are contradicting ﬁndings concerning the relation
betweenmyocardialMIBGuptakeandfunctionalintegrityof
theautonomousnervoussystem:Okaetal.[49],Spiegeletal.
[38],andShibataetal.[22]observedasigniﬁcantcorrelation
betweenmyocardialMIBGuptakeandbothsympatheticand
parasympathetic function. In contrast to that, Matsui et al.
[21], Haensch et al. [50], and Doi et al. [51] did not ﬁnd any
signiﬁcantcorrelationbetweenmyocardialMIBGuptakeand4 Parkinson’s Disease
sympatheticorparasympatheticfunction.Theseinconsistent
ﬁndings may be based on the diﬀerent methods to test the
autonomous functions.
5.2. Motor Phenotype of PD. Myocardial MIBG uptake
correlates with motor symptoms in PD; patients with tremor
dominant PD reveal a signiﬁcantly higher MIBG uptake
(Figure 2) than patients with the hypokinetic rigid type
of PD at each Hoehn and Yahr stage (Figure 3;[ 38, 52]).
Myocardial MIBG uptake correlates signiﬁcantly with the
severity of hypokinesia but not with the extent of resting or
postural tremor [19, 20, 38].
6. Pathophysiological Impact of
MIBG Scintigraphy
PD is characterized by a cerebral as well as extracranial
Lewybodytype-degeneration.Thecerebral—predominantly
nigrostriatal dopaminergic—Lewy body degenerations is
usually visualized by cerebral SPECT of the presynaptic
dopamine transporters (DAT). As mentioned above, MIBG
scintigraphy quantiﬁes exactly the extent of extracranial
myocardial sympathetic Lewy body degeneration. It is
unclear whether cerebral nigrostriatal dopaminergic and
extracranial sympathetic Lewy body degeneration occur
independently from each other or not. “Extreme” cases
might be possible in whom only the cerebral nigrostriatal
system but not the extracranial sympathetic system degener-
ates or vice versa. The intraindividual comparison between
cerebral nigrostriatal DAT SPECT and myocardial MIBG
scintigraphy may clarify this aspect: Spiegel et al. [53]a n d
Spiegel et al. [18] stated a signiﬁcant correlation between
cerebralnigrostriataldopaminergicandextracranialmyocar-
dial sympathetic degeneration at each Hoehn and Yahr
stage. No such correlation was found in healthy controls.
These ﬁndings suggest that cerebral and extracranial Lewy
body degenerations develop in a closely coupled manner
in PD.
7. Conclusions
MyocardialMIBGscintigraphyhelpstodiﬀerentiatebetween
PD and other parkinsonian syndromes in clinically diﬃ-
cult cases. Furthermore, the myocardial MIBG scintigraphy
allows insights into the pathophysiology of PD; myocardial
MIBG uptake correlates signiﬁcantly with the motor phe-
notype and with the nigrostriatal function (measured by
DAT SPECT). These facts suggest that cerebral nigrostriatal
dopaminergic degeneration and myocardial sympathetic
degeneration are closely coupled in PD.
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